These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17898741)

  • 21. Correcting Hatch-Waxman.
    Fernandes M
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract]   [Full Text] [Related]  

  • 22. Lost sleep...
    Pontious JM
    J Okla State Med Assoc; 2002 Aug; 95(8):523. PubMed ID: 12185985
    [No Abstract]   [Full Text] [Related]  

  • 23. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 24. The global impact of Indian generics on access to health.
    Ravinetto RM; Dorlo TP; Caudron JM; Prashanth NS
    Indian J Med Ethics; 2013; 10(2):118-20. PubMed ID: 23697493
    [No Abstract]   [Full Text] [Related]  

  • 25. The other path for follow-ons.
    Nat Biotechnol; 2008 Jul; 26(7):715. PubMed ID: 18612272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring the price of new drugs.
    Silversides A
    CMAJ; 2006 May; 174(11):1548-9. PubMed ID: 16717260
    [No Abstract]   [Full Text] [Related]  

  • 27. Generic drugs.
    Tuorto S; Hezel M; Marsh L; Eisenberg DP; Adusumilli PS
    Natl Med J India; 2005; 18(4):210-1. PubMed ID: 16252554
    [No Abstract]   [Full Text] [Related]  

  • 28. [Now no new drugs will be developed!].
    Lafolie P
    Lakartidningen; 2006 Jan 25-31; 103(4):225. PubMed ID: 16491556
    [No Abstract]   [Full Text] [Related]  

  • 29. Access to essential drugs prevented by pharmaceutical multinationals.
    Dev World Bioeth; 2001 May; 1(1):1-6. PubMed ID: 12870503
    [No Abstract]   [Full Text] [Related]  

  • 30. Antibiotics--an investment worth making?
    Christoffersen RE
    Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
    Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
    Sturm AC
    Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
    [No Abstract]   [Full Text] [Related]  

  • 33. Ichan the spoiler.
    Creswell J
    Fortune; 2005 Mar; 151(6):195-6, 198. PubMed ID: 15782883
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharma Dynamics: targeting safe, effective and affordable medication for South Africa and neighbouring countries.
    Cardiovasc J Afr; 2009; 20(1):85. PubMed ID: 19287824
    [No Abstract]   [Full Text] [Related]  

  • 35. Pfizer-Pharmacia: the postmerger.
    Wiggins P
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1761-3. PubMed ID: 14585052
    [No Abstract]   [Full Text] [Related]  

  • 36. Accord could make Canadian generics industry a 'rust bucket'.
    Hoag H
    Nat Med; 2012 Jul; 18(7):991. PubMed ID: 22772530
    [No Abstract]   [Full Text] [Related]  

  • 37. Biotechs go generic: the same but different.
    Ledford H
    Nature; 2007 Sep; 449(7160):274-6. PubMed ID: 17882194
    [No Abstract]   [Full Text] [Related]  

  • 38. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The patent is "engine" in drug development].
    Bergström R
    Lakartidningen; 2008 Mar 5-11; 105(10):752. PubMed ID: 18422246
    [No Abstract]   [Full Text] [Related]  

  • 40. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.